Search Results
Your search for all items matches 34730 pages
Showing 6451 - 6500
Christine A. Iacobuzio-Donahue, MD, PhD, on Pancreatic Cancer: Novel Insights Into Genetics and Evolution
Christine A. Iacobuzio-Donahue, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses her research on the evolutionary features of advanced stage pancreatic cancers and the insights that may be used to help improve patient outcomes (Abstract PL05).
ASTRO Issues Clinical Guideline on Radiation Therapy for Brain Metastases
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat patients with brain metastases. Evidence-based recommendations guide the multidisciplinary planning and delivery of advanced radiation therapy techniques to...
Comparison of 2020 NICE Criteria for Preoperative Radiotherapy in Rectal Cancer Treated by Surgery Alone With Established MRI Prognostic Factors
In a retrospective cohort study reported in The Lancet Oncology, Lord et al found that high-risk patients with rectal cancer treated with surgery alone who were more likely to benefit from preoperative radiotherapy were better selected using proven magnetic resonance imaging (MRI) prognostic...
Trends in Hysterectomy-Corrected Uterine Cancer Mortality and Racial/Ethnic Differences
In a study reported in JAMA Oncology, Clarke et al found that hysterectomy-corrected rates of mortality from uterine corpus cancer overall and from nonendometrioid carcinomas have increased in recent years, with mortality rates being highest in Black women. The study involved data from the U.S....
Addition of Ibandronate to Adjuvant Endocrine Therapy in Postmenopausal Women With ER-Positive Breast Cancer
In the Dutch phase III TEAM-IIB trial reported in the Journal of Clinical Oncology, Sonja B. Vliek, MD, and colleagues found that the addition of oral ibandronate to adjuvant endocrine therapy did not improve disease-free survival in postmenopausal women with estrogen receptor (ER)-positive stage I ...
Second-Line Tislelizumab vs Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
In the phase III RATIONALE-302 trial reported in the Journal of Clinical Oncology, Shen et al found that the anti–PD-1 antibody tislelizumab significantly improved overall survival vs chemotherapy in the second-line treatment of patients with advanced or metastatic esophageal squamous cell...
Why Are Black Women Still Dying at Higher Rates Than White Women From Breast Cancer?
What is so dismaying to me is that the statistic on survival for Black women with breast cancer has not changed since I was diagnosed with breast cancer 17 years ago. In 2005, Black women were 41% more likely to die of the disease than White women, even though Black women are less likely to be...
Short and Shorter Screening Tools for Food Insecurity
A survey of oncology registered dietitian nutritionists (RDNs)1 found that most of those surveyed were not using a validated assessment tool to identify food insecurity but expressed interest in obtaining the Six-Item Short Form of the Food Security Survey Module.2 The six-item food insecurity...
Assessing Food Insecurity Among Patients With Cancer
Food insecurity, particularly as it affects cancer survivors, is a serious problem, according to a survey of oncology registered dietitian nutritionists (RDNs) published in the Journal of the Academy of Nutrition and Dietetics.1 “Despite these concerns, most oncology RDNs interviewed are not using...
Music Interventions for Improving Psychological and Physical Symptoms in People With Cancer
Guest Editor’s Note: Cancer and its treatments are associated with both physical and psychological symptoms that can have substantial impact on patients’ quality of life. Music therapy is a complementary modality that is being increasingly used for cancer symptom management. In this article, Joke...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
From a Small Village in China to Cutting-Edge Clinical Cancer Research for Cynthia X. Ma, MD, PhD
Cynthia X. Ma, MD, PhD, was born in a small village in Hebei, a province in the Central China region. “I grew up in a poor village with less than 1,000 people. We had no medical services in our village, so we had to travel to the city to see a doctor, which was quite some distance away. In the...
DESTINY-Lung01: Is Trastuzumab Deruxtecan the Answer for HER2-Mutant Lung Cancer?
The human epidermal growth factor (HER) family of receptors are a well-established therapeutic target. Indeed, seminal studies conducted nearly 2 decades ago identified a key association between activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR, also known as...
DESTINY-Lung01: T-DXd Shows Durable Activity in Previously Treated Metastatic HER2-Mutant NSCLC
In a phase II trial (DESTINY-Lung01) reported in The New England Journal of Medicine, Bob T. Li, MD, PhD, MPH, of the Thoracic Oncology and Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York, and colleagues found that fam-trastuzumab deruxtecan-nxki (T-DXd) showed...
MSK Introduces The Starr Foundation Program for Discovery Science
Memorial Sloan Kettering Cancer Center (MSK) recently announced the establishment of The Starr Foundation Program for Discovery Science, a pioneering initiative made possible by a $50 million gift from The Starr Foundation. The program will support the work of scientists at the Sloan Kettering...
ASCO Honors 2022 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2022 ASCO Annual Meeting in Chicago. Hear from select award...
Expert Point of View: Barbara S. Norquist, MD
Discussant of the PRIME trial, Barbara S. Norquist, MD, Associate Professor of Obstetrics and Gynecology at the University of Washington, Seattle, noted that although all subgroups in the PRIMA study appeared to derive benefit from niraparib maintenance therapy, patients with homologous...
PRIME Trial: Niraparib Maintenance Therapy Improves Progression-Free Survival in Advanced Ovarian Cancer
A larger population of patients with newly diagnosed advanced ovarian cancer may be able to benefit from niraparib maintenance therapy, with an improved safety profile, according to phase III data presented at the 2022 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.1 Results ...
Updated Overall Survival Results From MONALEESA-3 Show Improved Overall Survival in Patients With HR-Positive/HER2-Negative Breast Cancer
In an updated analysis of the phase III MONALEESA-3 trial, which included postmenopausal patients with advanced/metastatic hormone receptor (HR)-positive, HER2-negative breast cancer, first-line treatment with ribociclib plus fulvestrant lengthened overall survival by approximately 16 months vs...
TUXEDO-1: Efficacy of T-DXd for Patients With HER2-Positive Breast Cancer and Active Brain Metastases
In the single-center phase II TUXEDO-1 trial of patients with advanced HER2-positive breast cancer, fam-trastuzumab-deruxtecan-nxki (T-DXd) showed efficacy in patients with active brain metastases, yielding intracranial responses in 73.3% of the population and a median progression-free survival of...
NCCN Announces Indiana University Melvin and Bren Simon Comprehensive Cancer Center Joins Member Institutions
The National Comprehensive Cancer Network® (NCCN®) recently announced that Indiana University Melvin and Bren Simon Comprehensive Cancer Center has joined the not-for-profit alliance of leading cancer centers as the 32nd member institution. NCCN was founded by 13 original Member Institutions in...
Penn Medicine Appoints Robert Vonderheide, MD, DPhil, to Second 5-Year Term as Director of Abramson Cancer Center
Robert H. Vonderheide, MD, DPhil, has been appointed to a second 5-year term as Director of the Abramson Cancer Center (ACC) at the University of Pennsylvania, following a highly successful tenure that saw 17 U.S. Food and Drug Administration approvals in oncology for therapies based on studies...
David Braun, MD, PhD, Joins Prostate and Urologic Cancers Program at Yale Cancer Center
Yale Cancer Center and Smilow Cancer Hospital welcome David Braun, MD, PhD, Assistant Professor of Medicine (Medical Oncology) and a member of the Center for Molecular and Cellular Oncology (CMCO). Dr. Braun cares for patients with kidney cancer. Dr. Braun received his PhD in Computational Biology ...
Sam Mbulaiteye, MBChB, MPhil, MMed, Named 2022 Scientist of the Year by Lymphoma Foundation of America
Sam Mbulaiteye, MBChB, MPhil, MMed, senior investigator in the Infections and Immunoepidemiology Branch, in the Division of Cancer Epidemiology & Genetics of the National Cancer Institute, was recently recognized by the Lymphoma Foundation of America with its 2022 Scientist of the Year Award....
J. Paul Taylor, MD, PhD, Named Scientific Director and Executive Vice President of St. Jude
J. Paul Taylor, MD, PhD, has been named Scientific Director and Executive Vice President of St. Jude Children’s Research Hospital. Dr. Taylor steps into the role during a pivotal time of growth for the hospital. Under its $11.5 billion, 6-year strategic plan, the institution’s scientific...
Absence of FAM19A4/miR124-2 DNA Methylation and Clinical Regression of High-Grade Cervical Intraepithelial Neoplasia
In the Dutch CONCERVE study reported in the Journal of Clinical Oncology, Kremer et al found that the absence of FAM19A4/miR124-2 DNA methylation was associated with a high rate of clinical regression of high-grade cervical intraepithelial neoplasia over 24 months among women treated with a...
Neoadjuvant Nivolumab and Platinum-Doublet Chemotherapy for Early NSCLC
On March 4, 2022, nivolumab was approved for use with platinum-doublet chemotherapy for resectable non–small cell lung cancer (NSCLC) in the neoadjuvant setting.1 The approval is the first for neoadjuvant therapy for early-stage NSCLC. Supporting Efficacy Data Approval was based on findings from...
AACR Honors Lee Ellis, MD, for Contributions to Education and Training in Cancer Research
The American Association for Cancer Research (AACR) has named Lee Ellis, MD, Professor of Colon and Rectal Surgery at The University of Texas MD Anderson Cancer Center, Houston, as the 2022 recipient of the AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in...
Expert Point of View: Julio Chavez, MD and Hayder Saeed, MD
Julio Chavez, MD, of the Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, was cautiously enthusiastic about these findings in CD30-positive lymphoma. “This clinical trial is novel, as it engages cord blood derived-NK cells to attack CD30-positive tumor cells using a...
Natural Killer Cells Precomplexed With Innate Cell Engager Show Activity in CD30-Positive Lymphoma
Natural killer (NK) cells derived from donated umbilical cord blood, activated with a novel bispecific antibody targeting CD16A and CD30 known as AFM13, have yielded responses in patients with pretreated and refractory CD30-positive lymphoma. The overall response rate was 89%, with 53% complete...
Treatment De-escalation in HPV-Associated Oropharyngeal Cancer Using Primary Radiotherapy vs Transoral Surgery
As reported in JAMA Oncology by David Palma, MD, PhD, and colleagues, enrollment in the phase II ORATOR2 trial, which was designed to evaluate overall survival after de-escalated treatment with primary radiotherapy vs transoral surgery in human papillomavirus (HPV)-related oropharyngeal squamous...
Going the Last Mile: Accelerating Delivery of Multiple Myeloma Therapies to All Patients
When I was diagnosed with multiple myeloma in 1996, I was given 3 years to live. At the time, there was little understanding of this disease, which was termed incurable. There were no new treatments, few drugs in the pipeline, hardly any clinical trials, and no multiple myeloma community or...
Nivolumab and Salvage Nivolumab/Ipilimumab for Previously Untreated Advanced Clear Cell Renal Cell Carcinoma
In a phase II trial (Hoosier Cancer Research Network GU16-260) reported in the Journal of Clinical Oncology, Michael B. Atkins, MD, and colleagues found that nivolumab monotherapy was active in previously untreated patients with advanced clear cell renal carcinoma, particularly among those with...
Expert Point of View: Mark Awad, MD, PhD
“In the past decade, major improvements in treating lung cancer have come from identification of mutations and development of drugs to target those mutations: EGFR, ALK, RET, HER2, and others. Finally, we can add KRAS as a druggable target,” stated invited discussant Mark Awad, MD, PhD, Clinical...
Association of Pathogenic Variants in Hereditary Cancer Genes With Additional Cancers and Non-neoplastic Diseases
In a study reported in JAMA Oncology, Zeng et al found that germline pathogenic variants in 23 hereditary cancer genes were associated with an increased risk of cancers not previously associated with the variants, as well as an increased risk of multiple non-neoplastic diseases. Study Details The...
2-Year Follow-up Shows Durable Responses With Sotorasib in KRAS G12C–Mutated Non–Small Cell Lung Cancer
Sotorasib, the first KRAS G12C inhibitor approved for the treatment of KRAS G12C–mutated non–small cell lung cancer (NSCLC), continues to demonstrate meaningful and durable efficacy at 2-year follow-up in the phase II CodeBreaK 100 trial. At a median follow-up of 24.9 months, the 2-year overall...
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Adult Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
On May 4, the FDA approved fam-trastuzumab deruxtecan-nxki for pretreated adult patients with unresectable or metastatic HER2-positive breast cancer. We highlight findings from the DESTINY-Breast03 trial that led to the regular approval, and also hear from Dr. Sara Hurvitz, of the University of...
Hematologic Oncology 2021–2022 Almanac
Ongoing evaluation of novel, targeted, and immunotherapies has led to exciting advances across the array of hematologic malignancies over the past year. The availability of new treatment options, along with emerging data on novel combinations and sequencing approaches, is rapidly changing...
Bispecific Antibodies With Multiple Targets Moving Forward in Multiple Myeloma
Poor outcomes are observed in patients with myeloma who are refractory to multiple classes of therapies, with the average patient experiencing disease progression in up to 6 months and living no longer than 6 to 15 months. Patients often rapidly cycle through regimens that use less effective or...
Expert Point of View: Joseph Mikhael, MD
The ASCO Post asked Joseph Mikhael, MD, Chief Medical Officer of the International Myeloma Foundation and Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (an affiliate of City of Hope Cancer Center), to comment on the GMMG-HD7...
Isatuximab-Containing Induction Therapy for Multiple Myeloma Increases Measurable Residual Disease Negativity
For the first-line treatment of newly diagnosed multiple myeloma, the percentage of patients achieving measurable residual disease (MRD, previously called minimal residual disease) negativity was significantly greater when the anti-CD38 monoclonal antibody isatuximab was added to a standard...
MAIA Trial: Daratumumab Added to Lenalidomide Plus Dexamethasone Improves Overall Survival in Transplant-Ineligible Multiple Myeloma
As reported in The Lancet Oncology by Thierry Facon, MD, of the Centre Hospitalier Universitaire de Lille, and colleagues, a prespecified interim analysis of overall survival in the pivotal phase III MAIA trial has shown a significant benefit with the addition of daratumumab to...
Maintenance Daratumumab Prolongs Progression-Free Survival in Newly Diagnosed Multiple Myeloma
As reported in The Lancet Oncology by Philippe Moreau, MD, of the University Hospital Hôtel-Dieu, Nantes, and colleagues, an interim analysis of part 2 of the phase III CASSIOPEIA trial has showed significantly prolonged progression-free survival with maintenance daratumumab vs observation...
Subcutaneous Daratumumab Added to Pomalidomide Plus Dexamethasone Improves Progression-Free Survival in Multiple Myeloma
As reported in The Lancet Oncology by Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, and colleagues, the phase III APOLLO trial has shown significantly improved progression-free survival with the addition of subcutaneous (SC) daratumumab to oral...
FDA Approvals in Hematologic Oncology 2021–2022
Over the past year, the U.S. Food and Drug Administration (FDA) granted approval to several novel drugs and new indications for older therapeutic agents used in hematologic oncology. Axicabtagene Ciloleucel: On April 1, 2022, axicabtagene ciloleucel (Yescarta) was approved for adult patients with...
BCMA-Directed CAR T-Cell Therapy Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
In the phase Ib/II CARTITUDE-1 trial reported in The Lancet, Jesus G. Berdeja, MD, and colleagues found that ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy with two B-cell maturation antigen (BCMA)-targeting single-domain antibodies, produced a high rate of...
Expert Point of View: Jane N. Winter, MD
Jane N. Winter, MD, moderator of the press conference on late-breaking abstracts at the 2021 American Society of Hematology (ASH) Annual Meeting & Exhibition, commented on the BELINDA study in the context of two investigations that had been previously reported at the same meeting, showing...
BELINDA Trial: CAR T-Cell Therapy Fails to Improve Outcomes in Aggressive Non-Hodgkin Lymphoma
The autologous chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel failed to improve event-free survival vs standard-of-care treatment strategies in patients with aggressive, relapsed or refractory non-Hodgkin lymphoma (NHL), according to results of the phase III BELINDA trial,...
Expert Point of View: Laurie H. Sehn, MD, MPH
The moderator of the session, Laurie H. Sehn, MD, MPH, Clinical Professor at the BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, Canada, called the results of the TRANSFORM trial “quite remarkable” and said chimeric antigen receptor (CAR) T-cell therapy has the...
TRANSFORM: Lisocabtagene Maraleucel Improves Outcomes in Relapsed or Refractory Large B-Cell Lymphoma
Chimeric antigen receptor (CAR) T-cell therapy with lisocabtagene maraleucel could prove to be the new standard-of-care treatment for patients with relapsed or refractory large B-cell lymphoma in the second-line setting, according to data presented at the 2021 American Society of Hematology (ASH)...
